Bicycle Therapeutics (BCYC) EBT Margin (2018 - 2026)
Bicycle Therapeutics (BCYC) reported EBT Margin of 6837.99% for Q1 2026, down 621816.0% on a YoY basis from N/an in Q1 2025, and down 12740.82% quarter-over-quarter from 53.25% in Q4 2025.
Bicycle Therapeutics (BCYC) EBT Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics has reported EBT Margin for 9 years, with the latest figure at 6837.99% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 621816.0% year-over-year to 6837.99%; the trailing twelve-month figure through Mar 2026 stood at 353.2% (down 24001.0% YoY), and the FY2025 full-year result was 310.61%, down 32709.0% from the prior year.
- EBT Margin for Q1 2026 stood at 6837.99%, down from 53.25% in the prior quarter.
- The five-year high for EBT Margin was 3416.24% in Q4 2024, with the low at 6837.99% in Q1 2026.
- Historically, EBT Margin has averaged 909.36% across 5 years, with a median of 619.84% in 2025.
- Annual changes were most pronounced in 2024 — EBT Margin surged 440202 bps — and 2026, when it plunged 621816 bps.
- Bicycle Therapeutics' EBT Margin stood at 386.1% in 2022, then plunged by 155 bps to 985.78% in 2023, then jumped by 447 bps to 3416.24% in 2024, then tumbled by 102 bps to 53.25% in 2025, then plunged by 12741 bps to 6837.99% in 2026.
- The last three EBT Margin figures came in at 6837.99% (Q1 2026), 53.25% (Q4 2025), and 501.92% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -6,837.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,837.99% |
| Dec 31, 2025 | -53.25% |
| Sep 30, 2025 | -501.92% |
| Jun 30, 2025 | -2,711.75% |
| Mar 31, 2025 | -619.84% |
| Dec 31, 2024 | 3,416.24% |
| Sep 30, 2024 | -2,027.28% |
| Jun 30, 2024 | -424.07% |
| Mar 31, 2024 | -258.78% |
| Dec 31, 2023 | -985.78% |
| Sep 30, 2023 | -889.87% |
| Jun 30, 2023 | -378.35% |
| Mar 31, 2023 | -810.50% |
| Dec 31, 2022 | -386.10% |
| Sep 30, 2022 | -940.30% |
| Jun 30, 2022 | -324.70% |
| Mar 31, 2022 | -724.95% |
| Dec 31, 2021 | -1,174.06% |
| Sep 30, 2021 | -348.33% |
| Jun 30, 2021 | -1,012.49% |